Bridgebio Pharma, INC Form 4 insider transactions

BridgeBio Pharma CEO Neil Kumar sold 26,156 shares of common stock for approximately $1.28 million as part of a pre-arranged trading plan.

BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, reported the disposition of 4,781 shares of common stock to cover tax obligations related to RSU vesting.

BridgeBio Pharma's President and CFO, Thomas Trimarchi, sold a portion of his common stock holdings, including shares withheld for tax obligations and sales under a pre-arranged 10b5-1 plan.

BridgeBio Pharma CEO Neil Kumar reported the vesting of 64,697 Restricted Stock Units and the subsequent sale of 32,855 shares for tax obligations.

A BridgeBio Pharma, Inc. director sold 300,000 shares of common stock in pre-planned transactions during August 2025.

BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, reported the sale of 1,000 shares of common stock at $45.44 per share, executed under a pre-arranged trading plan.

BridgeBio Pharma CEO Neil Kumar sold 80,000 shares of common stock for approximately $3.6 million in early August 2025, executed under a pre-arranged 10b5-1 trading plan.

BridgeBio Pharma Director Andrea Ellis exercised stock options and sold 17,167 shares for $49.00 each under a pre-arranged Rule 10b5-1 plan.

BridgeBio Pharma, Inc. CEO Neil Kumar executed sales of 80,000 shares of common stock in early July 2025 through pre-arranged Rule 10b5-1 plans.

Viking Global Investors LP, a 10% owner and director of BridgeBio Pharma, Inc., has reported the sale of 3.5 million shares of common stock for $44 per share.

BridgeBio Pharma Director Charles J. Homcy reported a planned future gift of 20,000 shares of common stock, scheduled for June 27, 2025, under a Rule 10b5-1 trading plan.

Hannah Valantine, a Director at BridgeBio Pharma, Inc., reported the sale of 4,707 shares of common stock across multiple transactions on June 26, 2025, totaling approximately $207,336.

BridgeBio Pharma, Inc. Director Hannah Valantine reported an acquisition of 1,752 shares of common stock at $14.24 per share, increasing her direct beneficial ownership.

Hannah Valantine, a Director at BridgeBio Pharma, Inc., filed an amended Form 4 to clarify direct and indirect common stock acquisitions made in December 2021.

BridgeBio Pharma, Inc. Director Frank McCormick sold 100,000 shares of common stock for approximately $4.42 million on June 24, 2025, under a Rule 10b5-1 trading plan.

BridgeBio Pharma, Inc. Director Andrew Lo was granted 6,589 restricted stock units and 8,425 stock options, aligning his interests with shareholders through a multi-year vesting schedule.

BridgeBio Pharma, Inc. Director Andrea Ellis reported the acquisition of 6,589 restricted stock units and 8,425 stock options on June 20, 2025, as part of the company's incentive plan.

BridgeBio Pharma, Inc. Director Jennifer E. Cook was granted Restricted Stock Units and stock options as part of her compensation, aligning her interests with the company's long-term performance.

BridgeBio Pharma, Inc. Director Frank McCormick was granted 6,589 restricted stock units and 8,425 stock options, vesting over three years, as part of his compensation package.

BridgeBio Pharma, Inc. director Eric Aguiar was granted 6,589 restricted stock units and options to purchase 8,425 shares of common stock, vesting over three years.

BridgeBio Pharma, Inc. Director Ronald J. Daniels was granted 6,589 restricted stock units and 8,425 stock options as part of his compensation, aligning his interests with shareholders.

BridgeBio Pharma, Inc. Director Ali J. Satvat was granted 6,589 Restricted Stock Units and options to purchase 8,425 shares of common stock, aligning his interests with shareholders.

BridgeBio Pharma, Inc. Director James C. Momtazee was granted 6,589 restricted stock units and 8,425 stock options, aligning his interests with long-term company performance.

BridgeBio Pharma, Inc. Director Charles J. Homcy was granted 6,589 restricted stock units and options to purchase 8,425 shares of common stock on June 20, 2025, as part of the company's incentive plan.

BridgeBio Pharma, Inc. Director Fred Hassan was granted 6,589 restricted stock units and 8,425 stock options, aligning his interests with shareholders through a multi-year vesting schedule.

BridgeBio Pharma, Inc. Director Douglas A. Dachille was granted 6,589 restricted stock units and 8,425 stock options as part of his compensation, aligning his interests with shareholders.

BridgeBio Pharma, Inc. director Hannah Valantine was granted restricted stock units and stock options, while also reporting a disposition of common stock at zero cost.

BridgeBio Pharma, Inc. Director Randal W. Scott was granted 6,589 restricted stock units and 8,425 stock options, aligning his interests with shareholders.

BridgeBio Pharma, Inc. Director Hannah Valantine exercised stock options and subsequently sold 4,292 shares of common stock on June 10, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

CEO Neil Kumar reports stock transactions including acquisition from RSU vesting, tax withholding, and sales under a 10b5-1 plan.